Biologics

BioPoly looks to raise $5m Series D for joint resurfacing tech

BY 

Schwartz Biomedical subsidiary BioPoly this week registered for a $5 million Series D round for its joint resurfacing technology.

The BioPoly material combines hyaluronic acid, a naturally occurring lubricant found in joint synovial fluid, and ultra-high-molecular-weight polyethylene, a biocompatible polymer. It’s designed to be used during arthroplasty procedures and won CE Mark approval in the European Union in June 2011.

READ THE REST AT MASSDEVICE

Print Friendly, PDF & Email
Tags

Josh Sandberg

Josh Sandberg is the President of Ortho Spine Partners and Partner for The De Angelis Group. He also serves as Co-Founder and Editor of OrthoSpineNews.

Related Articles

Leave a Reply

Your email address will not be published. Required fields are marked *

Back to top button
Close